Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Women Living With HIV
NCT06519994Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) comparing Artesunate vaginal inserts with Placebo vaginal inserts (2 arms). Primary endpoint: Clearance of type-specific HPV genotype(s) at 24 weeks. Started Jan 2025; status: completed.
02
Drugs
artesunate
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06519994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519994.